Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
| Sales | 34,124,100 | 28,541,400 | 28,318,400 | 24,539,800 | 22,319,500 |
| Cost of Goods | 7,082,200 | 6,629,800 | 7,312,800 | 5,483,300 | 4,721,200 |
| Gross Profit | 27,041,900 | 21,911,600 | 21,005,600 | 19,056,500 | 17,598,300 |
| Operating Expenses | 20,584,200 | 14,785,100 | 14,649,300 | 12,998,800 | 12,624,200 |
| Operating Income | 6,457,900 | 7,127,301 | 6,357,102 | 6,058,002 | 4,974,301 |
| Other Income | 96,700 | -320,901 | -201,602 | 1,171,898 | 291,599 |
| Pre-tax Income | 6,554,600 | 6,806,400 | 6,155,500 | 7,229,900 | 5,265,900 |
| Income Tax | 1,314,200 | 561,600 | 573,800 | 1,036,200 | 628,000 |
| Net Income Continuous | 5,240,400 | 6,244,800 | 5,581,700 | 6,193,700 | 4,637,900 |
| Net Income Discontinuous | N/A | N/A | N/A | N/A | 3,680,500 |
| Net Income | $5,240,400 | $6,244,800 | $5,581,700 | $6,193,700 | $8,318,400 |
| EPS Basic Total Ops | 5.82 | 6.93 | 6.15 | 6.82 | 8.93 |
| EPS Basic Continuous Ops | 5.82 | 6.93 | 6.15 | 6.82 | 4.98 |
| EPS Basic Discontinuous Ops | N/A | N/A | N/A | N/A | 3.95 |
| EPS Diluted Total Ops | 5.80 | 6.90 | 6.12 | 6.79 | 8.89 |
| EPS Diluted Continuous Ops | 5.80 | 6.90 | 6.12 | 6.79 | 4.96 |
| EPS Diluted Discontinuous Ops | N/A | N/A | N/A | N/A | 3.93 |
| EPS Diluted Before Non-Recurring Items | 6.32 | 7.94 | 8.16 | 7.93 | 6.04 |
| EBITDA(a) | $7,985,200 | $8,649,801 | $7,904,702 | $7,381,902 | $6,206,901 |